Literature DB >> 16041267

Expression of biologically active human TRAIL in transgenic pigs.

Regina Klose1, Elisabeth Kemter, Tanja Bedke, Iris Bittmann, Barbara Kelsser, Robert Endres, Klaus Pfeffer, Reinhard Schwinzer, Eckhard Wolf.   

Abstract

BACKGROUND: Xenotransplantation of porcine organs into human recipients is a potential option for overcoming the dramatic shortage of suitable donor organs. To date, transgenic modification of pig organs has achieved partial or temporal reduction of xenograft rejection by inhibition of hyperacute rejection. Expression of human tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL) in transgenic pigs might be a strategy for controlling posthyperacute rejection mechanisms mediated by cellular components of the immune system. The objective of this study was generation of a transgenic pig model to evaluate the potential of this strategy for xenotransplantation.
METHODS: Transgenic pigs were generated by microinjection of an expression vector for human TRAIL under control of the murine H-2K promoter. Expression of the transgene was analyzed by Western blot and immunohistochemistry. Biologic activity of TRAIL on transgenic porcine lymphocytes was evaluated in co-culture experiments using Jurkat and Hut 78.2 cells as targets.
RESULTS: In three lines of transgenic pigs, human TRAIL protein was detected in the membrane fractions of various tissues. Highest expression levels were observed in spleen and lung. Human TRAIL expression on porcine lymphocytes was augmented on activation of cells. Transgenic pig lymphoblasts induced apoptosis in Jurkat and Hut 78.2 cells, which was inhibited by neutralizing anti-TRAIL antibodies, demonstrating a TRAIL-specific effect.
CONCLUSIONS: Ubiquitous expression of human TRAIL was achieved in transgenic pigs without detrimental side effects. Pigs expressing biologically active human TRAIL will be used for future xenotransplantation experiments to modulate primate anti-pig cellular immune responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041267     DOI: 10.1097/01.tp.0000164817.59006.c2

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  16 in total

Review 1.  An update on xenotransplantation.

Authors:  E Cozzi; M Seveso; S Hutabba; S Fabris; L Cavicchioli; E Ancona
Journal:  Vet Res Commun       Date:  2007-08       Impact factor: 2.459

Review 2.  Pig-to-Primate Islet Xenotransplantation: Past, Present, and Future.

Authors:  Zhengzhao Liu; Wenbao Hu; Tian He; Yifan Dai; Hidetaka Hara; Rita Bottino; David K C Cooper; Zhiming Cai; Lisha Mou
Journal:  Cell Transplant       Date:  2017-02-03       Impact factor: 4.064

3.  Xenotransplantation as a model of integrated, multidisciplinary research.

Authors:  Emanuele Cozzi; Erika Bosio; Michela Seveso; Domenico Rubello; Ermanno Ancona
Journal:  Organogenesis       Date:  2009-01       Impact factor: 2.500

Review 4.  Genetic modifications of pigs for medicine and agriculture.

Authors:  Jeffrey J Whyte; Randall S Prather
Journal:  Mol Reprod Dev       Date:  2011-06-10       Impact factor: 2.609

Review 5.  Clinical lung xenotransplantation--what donor genetic modifications may be necessary?

Authors:  David K C Cooper; Burcin Ekser; Christopher Burlak; Mohamed Ezzelarab; Hidetaka Hara; Leela Paris; A Joseph Tector; Carol Phelps; Agnes M Azimzadeh; David Ayares; Simon C Robson; Richard N Pierson
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

Review 6.  Genetically modified pigs for biomedical research.

Authors:  Yonglun Luo; Lin Lin; Lars Bolund; Thomas G Jensen; Charlotte Brandt Sørensen
Journal:  J Inherit Metab Dis       Date:  2012-03-28       Impact factor: 4.982

Review 7.  Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses.

Authors:  Joachim Denner; Ralf R Tönjes
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

8.  Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function.

Authors:  Simone Renner; Christiane Fehlings; Nadja Herbach; Andreas Hofmann; Dagmar C von Waldthausen; Barbara Kessler; Karin Ulrichs; Irina Chodnevskaja; Vasiliy Moskalenko; Werner Amselgruber; Burkhard Göke; Alexander Pfeifer; Rüdiger Wanke; Eckhard Wolf
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

Review 9.  Genetic manipulation in pigs.

Authors:  David H Sachs; Cesare Galli
Journal:  Curr Opin Organ Transplant       Date:  2009-04       Impact factor: 2.640

Review 10.  Will Genetic Engineering Carry Xenotransplantation of Pig Islets to the Clinic?

Authors:  Elisabeth Kemter; Joachim Denner; Eckhard Wolf
Journal:  Curr Diab Rep       Date:  2018-09-18       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.